EditorialVials of a COVID-19 vaccine, developed by the Beijing drugmaker Sinovac, at the Butantan Institute in Sao Paulo on Feb. 11, 2021. (Victor Moriyama/The New York Times)
EditorialVials of a COVID-19 vaccine, developed by the Beijing drugmaker Sinovac, at the Butantan Institute in Sao Paulo on Feb. 11, 2021. (Victor Moriyama/The New York Times)